- Home
- ANAB vs ABSI Comparison
ANAB vs ABSI Comparison
Compare ANAB & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANAB | ABSI |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ANAB | ABSI |
|---|---|---|
| Price | $48.44 | $9.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | ★ $87.25 | $14.90 |
| AVG Volume (30 Days) | 510.1K | ★ 3.6M |
| Earning Date | 11-03-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | 10.64 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $234,603,000.00 | $4,534,000.00 |
| Revenue This Year | $17.97 | $39.03 |
| Revenue Next Year | $36.88 | $310.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $30.27 | $2.24 |
| 52 Week High | $73.30 | $12.06 |
Technical Indicators
Market Signals| Indicator | ANAB | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 48.08 |
| Support Level | $44.43 | $8.15 |
| Resistance Level | $51.27 | $11.73 |
| Average True Range (ATR) | 2.29 | 0.86 |
| MACD | 0.44 | -0.06 |
| Stochastic Oscillator | 58.84 | 26.66 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.